Response to First-Line Chemotherapy in Patients With Non–Small-Cell Lung Cancer According to Epidermal Growth Factor Receptor and K-RAS Mutation Status

Pfister, 2004, American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003, J Clin Oncol, 22, 330, 10.1200/JCO.2004.09.053 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Scagliotti, 2002, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer, J Clin Oncol, 20, 4285, 10.1200/JCO.2002.02.068 Kelly, 2001, Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial, J Clin Oncol, 19, 3210, 10.1200/JCO.2001.19.13.3210 Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial), J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038 Nishie, 2012, Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations, J Thorac Oncol, 7, 1722, 10.1097/JTO.0b013e31826913f7 Petrelli, 2012, Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials, Clin Lung Cancer, 2, 107, 10.1016/j.cllc.2011.08.005 Giaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1, J Clin Oncol, 22, 777, 10.1200/JCO.2004.08.001 Gatzemeier, 2007, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial, J Clin Oncol, 25, 1545, 10.1200/JCO.2005.05.1474 Mascaux, 2005, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis, Br J Cancer, 92, 131, 10.1038/sj.bjc.6602258 Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017 Massarelli, 2007, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, Clin Cancer Res, 13, 2890, 10.1158/1078-0432.CCR-06-3043 Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857 Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, 1, 33, 10.1016/S1470-2045(11)70318-7 Hotta, 2007, Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer, J Thorac Oncol, 2, 632, 10.1097/JTO.0b013e318074bc0d Cappuzzo, 2007, EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), J Thorac Oncol, 2, 423, 10.1097/01.JTO.0000268676.79872.9b Lee, 2006, Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer, Jpn J Clin Oncol, 36, 344, 10.1093/jjco/hyl039 Takano, 2008, EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan, J Clin Oncol, 26, 5589, 10.1200/JCO.2008.16.7254 Yoshimasu, 2011, Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer, J Thorac Oncol, 6, 1658, 10.1097/JTO.0b013e318221f71a Dixit, 1997, Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA, J Natl Cancer Inst, 89, 365, 10.1093/jnci/89.5.365 Kalikaki, 2010, Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status, Lung Cancer, 69, 110, 10.1016/j.lungcan.2009.09.010 Guan, 2013, KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy, Ann Surg Oncol, 4, 1381, 10.1245/s10434-012-2754-z Park, 2012, EGFR mutations as a predictive marker of cytotoxic chemotherapy, Lung Cancer, 77, 433, 10.1016/j.lungcan.2012.03.020 Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, 28, 744, 10.1200/JCO.2009.24.3030 Karachaliou, 2013, BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations, J Thorac Oncol, 3, 295, 10.1097/JTO.0b013e31827db621 Roth, 2011, Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis, Clin Lung Cancer, 6, 393, 10.1016/j.cllc.2011.04.005 Papadaki, 2012, ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer, J Thorac Oncol, 7, 663, 10.1097/JTO.0b013e318244bdd4 Olaussen, 2006, DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570 Reynolds, 2009, Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer, J Clin Oncol, 27, 5808, 10.1200/JCO.2009.21.9766